Clinical Trial Update: A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and pharmacokinetics of Aldurazyme (laronidase) in patients under 5 years old with mucopolysaccharidosis type I, including H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hurler Syndrome
• Hurler-scheie Syndrome
• Mucopolysaccharidosis Type
• Scheie Syndrome

Drugs mentioned

• Aldurazyme (Laronidase)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Mucopolysaccharidosis I, Hurler Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2009-06-16